Clinical Trials Logo

Recurrent Malignant Gliomas clinical trials

View clinical trials related to Recurrent Malignant Gliomas.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT00848523 Terminated - Clinical trials for Recurrent Malignant Gliomas

Study of LBH589 (Panobinostat) to Treat Malignant Brain Tumors

Start date: November 2008
Phase: Phase 2
Study type: Interventional

The drug LBH589 (panobinostat) is an experimental (investigational) drug that is being tested for recurrent (returning) malignant gliomas. An investigational drug is one that has not been approved by the U.S. Food and Drug Administration (FDA). It belongs to a new class of drugs called "histone deacetylase inhibitors." Histones are proteins located in the nucleus of cells that bind to DNA, the chemical that makes up genes. These proteins help control which genes are turned "on" and "off." Studies have shown that drugs like panobinostat (LBH589) may lead to tumor cell death.